| Income Statement | 2025-07-31 | |||
|---|---|---|---|---|
| Benefit from income taxes | -2,553 | |||
| Total revenue-Infusion Technology | 93 | |||
| Total revenue | 917 | |||
| Loss on impairment of goodwill | 3,100 | |||
| Total revenue-Rental Third Party | 197 | |||
| Total revenue-Rental Related Party | 112 | |||
| Total revenue-Product Revenue | 515 | |||
| Cost of product revenue-Infusion Technology Revenue | 106 | |||
| Cost of product revenue-Product Revenue | 28 | |||
| General and administrative | 13,781 | |||
| Research and development | 12,823 | |||
| Depreciation and amortization | 288 | |||
| In-process research and development expense | 0 | |||
| Loss from operations | -29,159 | |||
| Interest income | 1,996 | |||
| Realized gain on available-for-sale securities | 178 | |||
| Unrealized (loss) gain on investment - cyclo | -5,144 | |||
| Unrealized (loss) gain on convertible notes receivable, due from cyclo | -719 | |||
| Interest expense | 658 | |||
| Other income, net | 310 | |||
| Loss on initial investment in day three upon acquisition | 0 | |||
| Realized loss on investment in equity securities | 0 | |||
| Realized gain on investment - cyclo | 0 | |||
| Unrealized gain on investment - hedge funds | 0 | |||
| Recovery of receivables from cornerstone | 0 | |||
| Loss before income taxes | -33,196 | |||
| Equity in loss of day three | 0 | |||
| Consolidated net loss | -30,643 | |||
| Net loss attributable to noncontrolling interests | -123 | |||
| Net loss attributable to rafael holdings, inc | -30,520 | |||
| Basic (in dollars per share) | -1.04 | |||
| Basic (in shares) | 29,422,221 | |||
| Diluted (in dollars per share) | -1.04 | |||
| Diluted (in shares) | 29,422,221 | |||
Rafael Holdings, Inc. (RFL-WT)
Rafael Holdings, Inc. (RFL-WT)